Hints and tips:
...Lee, the grandson of Samsung founder Lee Byung-chul, was also accused of orchestrating a $3.9bn accounting fraud at the group’s biopharmaceutical unit in 2015....
...Lee, the grandson of Samsung founder Lee Byung-chul, is also accused of orchestrating a $3.9bn accounting fraud at the group’s biopharmaceutical unit in 2015 as part of the same case....
...“But many falling assets are hard to sell, like real estate and biopharmaceutical assets.”...
...Soon after Lee was paroled in August, Samsung Group announced a three-year, $206bn investment plan to expand its footprint in semiconductors, biopharmaceuticals, artificial intelligence and robotics....
...Soon after his release, Samsung announced a $206bn three-year investment plan to expand its footprint in semiconductors, biopharmaceuticals, artificial intelligence and robotics.The world’s biggest producer...
...He is scheduled to appear at the Seoul district court on Thursday over proceedings linked to allegations of a $3.9bn accounting fraud at Samsung’s biopharmaceutical unit....
...Sino Biopharmaceutical, a Hong Kong-listed generic drugs group, said on Monday it had acquired a 15 per cent stake in Sinovac Life Sciences, the subsidiary of Sinovac that has developed a Covid-19 vaccine...
...This is Sino Biopharmaceutical, which has acquired a 15 per cent stake in a subsidiary of Sinovac, to which it was previously unrelated....
...Sinovac is valued at more than $3bn — six times its market value last year, after Sino Biopharmaceutical acquired a 15 per cent stake in a subsidiary....
...Sinovac secured a cash injection of $515m from Hong Kong-listed Sino Biopharmaceutical in December that the group said would be used to improve vaccine sales capabilities and expand distribution in Asian...
...Ruud Dobber, executive vice-president of AstraZeneca’s biopharmaceuticals business, said the agreement “supports the management of our mature medicines to enable reinvestment into the pipeline and bringing...
...Financial regulators in Seoul previously ruled that Samsung BioLogics, a biopharmaceutical unit of Samsung Group, inflated the value of its affiliate Samsung Bioepis by $3.9bn in 2015....
...In another incident highlighting governance failings, eight employees from Samsung group affiliates were last week found guilty of destroying evidence linked to a $3.9bn accounting fraud in the biopharmaceutical...
...Samsung has been trying to expand into biopharmaceuticals and healthcare in recent years....
...have now been arrested in recent weeks as South Korean prosecutors broaden an investigation into whether top executives covered up evidence linked to an alleged accounting fraud in 2015 at the company’s biopharmaceutical...
...Five employees from Samsung Electronics and three from the group’s biopharmaceutical affiliates Samsung BioLogics and Samsung Bioepis have been arrested in recent months....
...Samsung has also been expanding into biopharmaceuticals and healthcare in recent years....
...(FT) News round-up Merck agrees $1bn deal to buy biopharmaceutical company Peloton (FT) Billionaire Hinduja brothers weigh bid for India's Jet Airways (Reuters) Ana Botín’s comments on Dia prompt regulator...
...Samsung in August outlined a three-year investment plan that involves pouring more than $22bn into technologies including AI, automotive electronics components and biopharmaceuticals....
...Samsung’s latest deal comes after the company in August announced it would pour Won25tn ($22.2bn) into new business areas, including artificial intelligence, 5G, automotive electronics components and biopharmaceuticals...
...The South Korean financial watchdog in July ruled that the company, the biopharmaceutical unit of Samsung Group, had in 2015 intentionally omitted key information that could have affected the valuation of...
...When Samsung decided to try its luck at biopharmaceuticals in 2010, its operations consisted of a 12-person team working out of the basement of a hospital laboratory....
...Funds would also be allocated to developing advanced manufacturing processes, new chemical materials and biopharmaceuticals, he said....
...Samsung will, over the next three years, plough more than $22bn into technologies including artificial intelligence, automotive electronics components and biopharmaceuticals....
...Shares of Samsung BioLogics fell by a fifth after South Korea’s financial regulator said the biopharmaceutical company had violated accounting rules....
International Edition